Hypersecretory Conditions is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hypersecretory Conditions have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hypersecretory Conditions compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hypersecretory Conditions overview
Hypersecretory Condition is a group of disorders characterized by hypersecretion of gastric acid also known as hypergastrinemia. This condition can result in peptic ulcers, GERD, gastrointestinal hemorrhage causing a predominant mortality and morbidity. Underlying diseases, helicobacter pylori infection, gastric outlet obstruction, chronic renal failure and idiopathic causes results to hypersecretion of gastric juice. Diagnosed by the gastrin levels and gastric acid secretion range. Proton pump inhibitors are first line of therapy followed by antibiotics in H. Pylori infections, and supportive care and diet balance by avoiding foods that are citrus in nature. Surgical options in complicated cases.
For a complete picture of PTSR and LoA scores for drugs in Hypersecretory Conditions, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
